Re: LLTP. Thanks - It appears to be below my threshold for risk (which is already pretty low, unfortunately), but has potential. Having a unique profile (naltrexone spray) seems like a good product for overdoses outside a medical facility. I see there is a 1:100 split coming up at some point (unless it already happened - yikes if it did), so it might be worth watching.
They are going after the same target (opiate overdose/respiratory depression) as another dog of mine, Cortex (CORX), which also showed incredible potential...once. It does look as though Lightlake's product would be much closer to approval/market than Cortex, given naltrexone is already an approved drug. However, Cortex would seem to have stronger IP and more ultimate upside. Since both those companies trade @ same price with @ the same MC, maybe there could be a synergistic merger in the future...misery loves company, lol.
